These findings suggested that enhanced expression of FTO/SP1/AURKB signaling in GC might also in-deeply control its malignant progression through regulation of tumor immune microenvironment, which could be very detrimental to the treatment and prognosis of patients. This evidence concerns the gene AURKB and gastric cancer.